With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions – STAT

Biogen, desperate to reverse the turmoil surrounding its controversial Alzheimer’s treatment Aduhelm, has a shopping list of potential acquisitions, STAT has learned. And the company’s risk-averse bo… [+1577 chars]

View The Article On: STAT

Powered By

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

To Top